- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioAlliance Pharma SA (Euronext Paris - Code Isin : FR0010095596 - BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections, announced today that it will take part in the SmallCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on April 26-27 in Paris.
Dominique Costantini, BioAlliance President and CEO, and Nicolas Fellmann, Chief Financial Officer, will meet institutional investors during the two days for one-on-one discussions to explain company strengths and strategic priorities.
BioAlliance will also be present at the following conferences:
- BioEquity Europe in Glasgow, May 21-22, 2007
- Piper Jaffray Healthcare Conference, London, June 20-21, 2007
About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections.
Specialty pharma targets the development and marketing of drugs for specialist markets and selected populations. This business model, unlike that of "big pharma" which targets general medicine, offers faster product development, lower R&D costs, smaller sales teams, and hence higher margins and fast growth.
The Company is developing three broad product ranges based on the Lauriad® mucoadhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.
The Loramyc® (miconazole Lauriad®) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In October 2006, the company obtained Marketing Authorization for this product in France. A pivotal Phase III trial of Loramyc® is ongoing in the US for the same indication. The company has submitted a Phase III protocol for a second product, acyclovir Lauriad®, an oral herpes treatment. Approval was granted in Australia, France and the Czech Republic in February 2007. A Phase II/III trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology started in Europe in December 2006. This product has been granted orphan drug status by the EMEA and the FDA.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com .
For more information, please click here
BioAlliance Pharma SA
President and CEO
Tel : +33 1 45 58 76 01
Chief Financial Officer
Tel : +33 1 45 58 71 00
Andrew Lloyd & Associates
Tel : +33 1 56 54 07 00
Juliette DOS SANTOS
Tel : +33 1 56 54 07 04
Tel : +33 1 53 67 36 33
Tel : +33 1 53 67 35 74
Copyright © BioAlliance Pharma SAIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New Nanodrug Produced in Iran from Milk Thistle May 4th, 2015
Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015